Reduction in migraine daysfollow up: 6 months
|
The mean reduction in migraine days was − 2.6 days
|
The mean reduction in migraine days in the intervention group was 1.9 days fewer (2.3 fewer to 1.4 fewer)
|
–
|
1330(2 RCT)
| ⨁⨁⨁⨁HIGH |
Treatment with galcanezumab 240 mg results in reduction in migraine days compared with placebo.
|
Reduction in use of acute attack medication follow up: 6 months
|
The mean reduction in use of acute attack medication was − 2.1 days
|
The mean reduction in use of acute attack medication in the intervention group was 1.7 days fewer (1.9 fewer to 1.4 fewer)
|
–
|
1330(2 RCT)
| ⨁⨁⨁⨁HIGH |
Treatment with galcanezumab 240 mg results in reduction in use of attack medication compared with placebo.
|
Improvement in functional MSQ RFR score follow up: 6 months
|
The mean improvement in functional MSQ RFR score was 22.2 points
|
The mean improvement in functional MSQ RFR score in the intervention group was 7.3 points higher (5.6 higher to 9.1 higher)
|
–
|
1330(2 RCT)
| ⨁⨁⨁⨁HIGH |
Treatment with galcanezumab 240 mg results in improvement in functional MSQ RFR score compared with placebo.
|
At least 50% reduction in days of migrainefollow up: 6 months
|
372 per 1000
|
586 per 1000(522 to 658)
|
RR 1.5738(1.4013 to 1.7675)
|
1330(2 RCT)
| ⨁⨁⨁⨁HIGH |
Treatment with galcanezumab 240 mg results in at least 50% reduction of days of migraine compared with placebo.
|
Serious adverse events follow up: 6 months
|
11 per 1000
|
16 per 1000(6 to 41)
|
RR 1.3953(0.5347 to 3.6413)
|
1330(2 RCT)
| ⨁⨁⨁⨁HIGH |
Treatment with galcanezumab 240 mg results in a small possibly unimportant effect in serious adverse events occurrence compared with placebo.
|
Mortality follow up: 6 months
|
0 per 1000
|
0 per 1000(0 to 0)
|
not estimable
|
1330(2 RCT)
| |
No deaths occurred during the double-blind treatment phase of the trial.
|